HUTCHMED (China) Limited HCM
14.91 USD -0.18 (-1.16%)
Nov 12, 2026, 2:54 PM EST
14.85 Day range 15.00
9.99 52-week range 16.05
- YTD
- +11.82%
- 1 year
- -2.45%
News
globenewswire.com Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update 52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893's potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen…
prnewswire.com Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring – Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two…
benzinga.com Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent…
benzinga.com Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and…
benzinga.com HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned — ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS…- benzinga.com HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO —ORPATHYS plus…
benzinga.com Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —Application…
benzinga.com HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript HUTCHMED (China) (NASDAQ:HCM) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For…
benzinga.com Why Is HUTCHMED Stock Soaring Thursday? HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies…
benzinga.com Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake and other stocks rallied.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…
benzinga.com Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.- benzinga.com HUTCHMED Signs GSK Cancer Drug Deal Worth Up To $1.3B, Gets $110M Upfront HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a…
benzinga.com AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhertu breast cancer combination.
benzinga.com Reported Earlier, HUTCHMED Reports Late-Stage Results For New Lung Cancer Treatment Combo HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced…
benzinga.com AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu while halting a volrustomig study.
benzinga.com Reported Sunday, HUTCHMED Says ORPATHYS Plus TAGRISSO Achieved Statistically Significant, Clinically Meaningful PFS And OS Improvements In MET-Driven EGFR-Mutated Lung Cancer First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung…
benzinga.com HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.09 per share. This is a 96.55 percent decrease over earnings of $2.61 per share from the same period last year. The company reported…- benzinga.com Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14 Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.
- benzinga.com B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17 B of A Securities analyst Alec Stranahan maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $20 to $17.
benzinga.com HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trial HUTCHMED reported positive Phase 2 data for fanregratinib in advanced ICC as China reviews the drug.- benzinga.com Reported Earlier, HUTCHMED's Fanregratinib Achieves 42.5% Objective Response Rate In Pivotal Phase II Study For Intrahepatic Cholangiocarcinoma With FGFR2 Fusions — Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —— Fanregratinib holds promise as a new treatment option for…
benzinga.com Reported Earlier, HUTCHMED Says Sovleplenib Shows Favorable Safety Profile With Fewer Grade 3 Adverse Events Than Placebo — Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile ——The ESLIM-02 study underscores sovleplenib's potential to address critical unmet needs in a treatment…- benzinga.com HUTCHMED And Innovent Biologics Announce That The Joint New Drug Application For The Combination Of Elunate And Tyvyt Has Been Granted Approval By The China National Medical Products Administration Companies granted approval by the China National Medical Products Administration ("NMPA") for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior…
- benzinga.com China Authority Accepts And Grants Priority Review To Hutchmed's Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia Patients Who Have Had An Insufficient Response To Prior Glucocorticoid Treatment HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application ("NDA") for sovleplenib for the treatment of adult patients with warm antibody autoimmune…
benzinga.com B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20 B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $21 to $20.- benzinga.com HUTCHMED Recalls Cancer Drug Tazverik in China After US Withdrawal Over Safety Risks HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology therapy licensed from Epizyme, Inc.…
benzinga.com Earnings Scheduled For March 5, 2026 - benzinga.com HUTCHMED (China) FY EPS $2.62 Beats $1.43 Estimate, Sales $548.512M Miss $591.425M Estimate HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $2.62 per share which beat the analyst consensus estimate of $1.43 by 83.22 percent. This is a 1090.91 percent increase over earnings of…
benzinga.com An Overview of HUTCHMED (China)'s Earnings - benzinga.com Reported Earlier, HUTCHMED Reports Phase III SACHI Trial Published In The Lancet Demonstrating Improved PFS With Savolitinib Plus Osimertinib Versus Chemotherapy First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment.Savolitinib and…
benzinga.com Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a planned China drug filing in 2026 as competition in blood disorders intensifies.- benzinga.com HUTCHMED Announces China NDA Acceptance And Priority Review For Fanregratinib Supported By Phase II Registration Trial Results NDA supported by results from a Phase II registration trial in China —— Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in compariso
- benzinga.com Reported Earlier, HUTCHMED Begins First-In-Human Global Clinical Program For ATTC Candidate HMPL-A251 In Solid Tumors — First-in-human trial of candidate from the next-generation ATTC platform —— Simultaneous China and global clinical development strategy to expedite development process —
benzinga.com Reported Sunday, HUTCHMED Unveils Innovative ATTC Platform Integrating Antibodies And Small-Molecule Inhibitors To Deliver Synergistic Anti-Tumor Activity And Improved Safety — HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —— Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK…- benzinga.com HUTCHMED Presents HMPL-A251 Preclinical Data At AACR-NCI-EORTC Showing Potent HER2-Targeted PI3K/PIKK Inhibitor With Robust Antitumor Activity And Low Toxicity First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities Unique, highly potent PI3K/PIKK…
- benzinga.com Reported Earlier, HUTCHMED To Present New And Updated Clinical Data On Fruquintinib, Savolitinib And Surufatinib At ESMO Congress 2025 In Berlin new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology ("ESMO") Congress 2025, taking place on October 17-21,…
- benzinga.com Morgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75 Morgan Stanley analyst Jack Lin downgrades HUTCHMED (China) (NASDAQ:HCM) from Equal-Weight to Underweight and lowers the price target from $18 to $13.75.
benzinga.com IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday - benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28 B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and raises the price target from $27 to $28.
- benzinga.com HUTCHMED Receives China NMPA Approval For ORPATHYS In Combination With TAGRISSO For Treatment Of EGFRm NSCLC Patients With MET Amplification After Progression On EGFR Inhibitor Therapy Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —The only all-oral combination treatment option for…
- benzinga.com Reported Sunday, HUTCHMED Highlights SACHI Phase III Data At ASCO 2025: Savolitinib Plus Osimertinib Shows Significant PFS Benefit In EGFR+ NSCLC With MET Amplification — The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study —
- benzinga.com Reported Earlier, HUTCHMED Wraps Enrollment In Phase II Gastric Cancer Trial For Savolitinib, Targets Late 2025 China Filing The China's National Medical Products Administration ("NMPA") has granted Breakthrough Therapy Designation to savolitinib for the treatment of locally advanced or metastatic gastric cancer or GEJ…
benzinga.com Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday - benzinga.com Reported Earlier, HUTCHMED Presents SAVANNAH Trial Results For Savolitinib + TAGRISSO In MET-Driven NSCLC At European Lung Cancer Congress SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address…
benzinga.com Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength Hutchmed forecasts 2025 oncology revenue of $350–$450 million after a strong 65% growth in 2024, driven by Fruzaqla sales and new regulatory approvals in China.- benzinga.com HUTCHMED Projects 2025 Oncology Revenue Between $350M–$450M, Backed By Strong Balance Sheet FINANCIAL GUIDANCEHUTCHMED provides full year 2025 guidance for Oncology/Immunology consolidated revenue of $350 million to $450 million. HUTCHMED's work in 2025 and beyond will be supported by its…
- benzinga.com HUTCHMED (China) FY 2024 GAAP EPS $0.22 Down From $0.58 YoY, Sales $630.20M Down From $838.00M YoY HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.22 per share. This is a 62.07 percent decrease over earnings of $0.58 per share from the same period last year. The company reported…